MaiRa is the first test on the market, based on a maternal blood sample that that makes it possible to identify the risk of early-onset preeclampsia at an early stage.
Pregnancy is a dynamic process. Some complications can develop without obvious symptoms in their early stages, which makes them difficult to detect until they are already advanced.
These complications include preeclampsia , a condition that can develop silently during pregnancy and affect both the health of the mother and the wellbeing of the baby.
Prevention begins with the right information.
La Preeclampsia is a pregnancy complication characterised by the onset of high blood pressure during gestation and the possible involvement of various organs. It can affect both the health of the mother and the wellbeing of the baby..
Results must always be interpreted by a healthcare professional.
Despite its impact, early detection of the risk of preeclampsia remains limited in clinical practice, as diagnosis is based mainly on the appearance of clinical symptoms. This entails:
The real challenge is not only to treat preeclampsia when it appears, but to identify the risk in time in order to prevent it.
Detecting the risk from early stages makes it possible to adapt medical monitoring and reduce uncertainty.
At iPremom we develop innovative solutions for early prenatal care.
Our approach combines:
MaiRa is a prenatal test developed by iPremom that helps to identify the risk of preeclampsia at an early stage.
MaiRa is a predictive test developed by iPremom that helps to identify, at an early stage, the risk of preeclampsia, one of the main complications of pregnancy.
It is performed from a simple maternal blood sample and provides relevant information from early stages, when prevention can be more effective.
Preeclampsia: a complication that can appear without warning
MaiRa analyses the circulating cell-free RNA present in the maternal blood —coming from both the placenta and the baby— and, by means of proprietary predictive software developed and scientifically validated by iPremom, estimates the risk of developing preeclampsia.
It is not a diagnostic test. It is a risk-assessment tool that helps you to anticipate.
Step by step
From week 9 of pregnancy.
The circulating cell-free RNA is detected and analysed using advanced molecular technology and a scientifically validated predictive algorithm.
Within 21 days, a report is generated with the risk estimate.
Your healthcare professional interprets the results and adapts the monitoring of the pregnancy.
MaiRa provides:
Results must always be interpreted by a healthcare professional.
MaiRa can be useful for pregnant women who want to have early information about their pregnancy, regardless of whether or not they have known risk factors.
It may be especially advisable if there are:
Your doctor will help you to know whether this test is right for you.
The peace of mind of knowing that your pregnancy is cared for with rigour and knowledge.
Download here all the documentation needed to carry out the test: instructions, request form, and information sheet and informed consent.
Instructions for clinics and sample collection centres
Test request form (TRF)
Information sheet and consent (IC)
Yes, the test is performed from a maternal blood sample and poses no risk.
The standard turnaround time for results is 3 weeks from receipt of the sample
Your doctor will assess the result and adapt the monitoring of the pregnancy.
Yes, MaiRa can be integrated into the usual monitoring of the pregnancy.
Preeclampsia is a pregnancy complication characterised by the onset of high blood pressure, organ damage and other symptoms. It can progress to severe forms such as eclampsia (seizures), with a risk to maternal and fetal life.
Preeclampsia affects approximately 1 in every 20 pregnancies globally. Its impact can be significant if it is not detected in time. There are risk factors that increase this incidence, such as hypertension or advanced maternal age.
Yes. In many women, preeclampsia does not present clear symptoms in its early stages, which makes early detection difficult without specific tools.
Because anticipating it makes it possible to:
Early information helps
